(-0.05%) 5 466.53 points
(-0.41%) 38 951 points
(0.31%) 17 773 points
(0.25%) $81.03
(-3.23%) $2.67
(-0.91%) $2 309.70
(-0.39%) $28.76
(1.44%) $1 000.60
(0.30%) $0.936
(0.81%) $10.69
(0.34%) $0.791
(-0.27%) $87.25
Live Chart Being Loaded With Signals
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer...
Stats | |
---|---|
本日の出来高 | 81 202 |
平均出来高 | 0 |
時価総額 | 345 164 |
EPS | $-2.16 ( Q1 | 2024-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00100 (142.86%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-27 | Sr One Capital Management, Llc | Sell | 430 578 | Common Stock |
2023-11-27 | Sr One Capital Management, Llc | Sell | 178 585 | Common Stock |
2023-11-15 | Worland Stephen T | Buy | 5 979 | Common Stock |
2023-11-15 | Byrnes Michael | Buy | 4 524 | Common Stock |
2023-09-09 | Loewy Caroline M | Buy | 40 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
28.90 |
Last 94 transactions |
Buy: 4 047 347 | Sell: 1 063 888 |
eFFECTOR Therapeutics, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
eFFECTOR Therapeutics, 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-111 000 (0.00 %) |
EPS: | $-16.37 |
FY | 2023 |
収益: | $0 |
総利益: | $-111 000 (0.00 %) |
EPS: | $-16.37 |
FY | 2022 |
収益: | $3.55M |
総利益: | $3.50M (98.51 %) |
EPS: | $-7.85 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
eFFECTOR Therapeutics,
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。